Changes in inflammatory cytokine networks in myasthenia gravis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Uzawa, Akiyuki ^a   Kanai, Tetsuya ^a   Kawaguchi, Naoki ^a,b   Oda, Fumiko ^a   Himuro, Keiichi ^a   Kuwabara, Satoshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Neurology Chiba Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; APRIL PROTEIN; CHOLINERGIC RECEPTOR; CYTOKINE; INTERLEUKIN DERIVATIVE; TNFSF13 PROTEIN, HUMAN;

ADULT; AGED; BLOOD; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MYASTHENIA GRAVIS;

ADULT; AGED; ANTIBODIES; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84968680304     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25886     Document Type: Article

References (25)

1. Gilhus, N. E., & Verschuuren, J. J. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 14, 1023-36 (2015).
2. Tüzün, E., Scott, B. G., Goluszko, E., Higgs, S., & Christadoss, P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol. 171, 3847-54 (2003).
3. Uzawa, A., Kawaguchi, N., Himuro, K., Kanai, T., & Kuwabara, S. Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clin Exp Immunol. 176, 232-7 (2014).
4. Uzawa, A., et al. Increased serum peroxiredoxin 5 levels in myasthenia gravis. J Neuroimmunol. 287, 16-8 (2015).
5. Uzawa, A., Kawaguchi, N., Kanai, T., Himuro, K., & Kuwabara, S. Serum high mobility group box 1 is upregulated in myasthenia gravis. J Neurol Neurosurg Psychiatry 86, 695-7 (2015).
6. Roche, J. C., et al. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve. 44, 278-80 (2011).
7. Zheng, S., et al. Expression of interleukin-22 in myasthenia gravis. Scand J Immunol. 78, 98-107 (2013).
8. Murai, H., et al. Clinical features and treatment status of adult myasthenia gravis in Japan. Clin Exp Neuroimmunol. 5, 84-91 (2014).
9. Jaretzki, A. 3rd et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55, 16-23 (2000).
10. Yang, H., et al. Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile. Inflamm Res. 59, 197-205 (2010).
11. Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A., & Hymowitz, S. G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 29, 71-109 (2011).
12. Liao, Y. C., et al. IL-19 induces production of IL-6 and TNF-Alpha and results in cell apoptosis through TNF-Alpha. J Immunol. 169, 4288-97 (2002).
13. Liao, S. C., et al. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol. 173, 6712-8 (2004).
14. Matsuo, Y., et al. Interleukin 19 reduces inflammation in chemically induced experimental colitis. Int Immunopharmacol. 29, 468-75 (2015).
15. Horiuchi, H., et al. Interleukin-19 acts as a negative autocrine regulator of activated microglia. PLos one. 10, e0118640 (2015).
16. Hsu, Y. H., et al. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum. 54, 2722-33 (2006).
17. Sa, S. M., et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 178, 2229-40 (2007).
18. Li, H. H., et al. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin Immunol. 129, 277-85 (2008).
19. Rutz, S., Wang, X., & Ouyang, W. The IL-20 subfamily of cytokines-from host defence to tissue homeostasis. Nat Rev Immunol. 14, 783-95 (2014).
20. Koltsida, O., et al. IL-28A (IFN-? 2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med. 3, 348-61 (2011).
21. Mennechet, F. J., & Uzé, G. Interferon-lambda-Treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood. 107, 4417-23 (2006).
22. Yilmaz, V., et al. B cells produce less IL-10, IL-6 and TNF-α in myasthenia gravis. Autoimmunity 48, 201-7 (2015).
23. Collison, L. W., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566-9 (2007).
24. Vincent, F. B., et al. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24, 203-215 (2013).
25. Thangarajh, M., et al. The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis. J Neuroimmunol. 178, 161-6 (2006).